GIST: did the treatment follow the guidelines?

GIST is short for gastrointestinal stromal tumor, a rare cancer that grows in the wall of the digestive tract, most often the stomach or small intestine. Because it is rare, many hospitals see only a handful of cases a year, and the treatment playbook is specific enough that steps get missed.

The clinical practice guidelines for GIST are unusually clear-cut. They spell out when surgery alone is enough, who needs drug therapy afterward, and which drug fits which tumor mutation. That makes GIST care unusually easy to check after the fact. These are the decision points we check a GIST record against, each with its guideline page cited.

The decisions that matter

• Risk after surgery. Tumor size, location, and how fast the cells were dividing (the mitotic rate on the pathology report) put a resected GIST into a risk category. High-risk patients should be offered imatinib (Gleevec) for three years after surgery. Skipping that conversation is one of the most consequential misses in GIST care.
• Mutation testing. Before long-term drug therapy starts, the tumor should be genotyped. This is not academic. A tumor with the PDGFRA D842V mutation does not respond to imatinib at all; the guideline drug for it is avapritinib. A KIT exon 9 tumor calls for a doubled imatinib dose. Without the test, a patient can spend months on a drug that was never going to work.
• The drug sequence. When GIST spreads or comes back, the guidelines list a specific order: imatinib first, then sunitinib, then regorafenib, then ripretinib. A patient told there were no options left after one or two of these still had approved, guideline-listed lines ahead of them.
• Follow-up imaging. After a GIST is removed, the guidelines call for scheduled CT scans for years, because recurrences caught early can still be treated well. A record with no surveillance imaging at all is a red flag.
• Limited progression. If the disease progresses in one spot while staying controlled everywhere else, the guidelines support treating that one spot locally (ablation, embolization, or surgery) while continuing the drug, rather than abandoning a therapy that is still mostly working.

What a deviation looks like

A high-risk stomach GIST removed cleanly, then no drug therapy and no scans, and a recurrence two years later. Imatinib started without mutation testing on a tumor that turns out to be D842V. Treatment stopped after second line with a note that nothing more could be done. Findings like these are not proof of negligence. They are specific, citable questions to put to a clinician or a lawyer.